Ficlatuzumab
Based on 1 Customer Validation
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.
For research use only. We do not sell to patients.
- Purity : 99.39%
- CAS No.: 1174900-84-5
- Molecular Weight:144.5 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99192
EmibetuzumabBivalent MET Antibody -
HY-P99217
RilotumumabAnti-HGF mAb -
HY-13404
Capmatinibc-MET Kinase Inhibitor -
HY-P99250
OnartuzumabMET Inhibitor -
HY-14721
Tepotinibc-Met Inhibitor -
HY-10338
ForetinibMET/VEGFR2/KDR Inhibitor -
HY-125017
Bozitinibc-MET Kinase Inhibitor -
HY-116000
Glumetinibc-Met Inhibitor -
HY-50683
JNJ-38877605c-Met/HGFR Inhibitor -
HY-12019
SGX-523MET Inhibitor -
HY-137455
Terevalefimc-Met Receptor Activator
Biological Activity
Description
Isotype
Human IgG1(K214R) kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
HGF/SF
In Vitro
Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion[1].
Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells[1].
Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells[1].
Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- BrdU Incorporation Assay
- Cell migration
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Cell invasion
- MTT Cell Proliferation Assay
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human HGF Protein can bind Ficlatuzumab. The EC50 for this effect is 3.15 ng/mL.
Chemical Information
-
CAS No. 1174900-84-5
-
Appearance Liquid
-
Molecular Weight 144.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Ficlatuzumab]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ficlatuzumab Related Classifications
HY-P99196 Related Classifications
Powered by Bioz